Hurdles for Phage Therapy (PT) to Become a Reality

Buch | Softcover

484 Seiten

2019
MDPI (Verlag)
978-3-03921-391-7 (ISBN)

Keine Verlagsinformationen verfügbar

Artikel merken

Alternative treatment modes for antibiotic-resistant bacterial pathogens have become a public health priority. Bacteriophages are bacterial viruses that infect and lyse bacterial cells. Since bacteriophages are frequently bacterial host species-specific and can often also infect antibiotic-resistant bacterial cells, they could represent ideal antimicrobials for fighting the antibiotic resistance crisis. The medical use of bacteriophages has become known as phage therapy. It is widely used in Russia, where phage cocktails are sold in pharmacies as an over-the-counter drug. However, no phage product has been registered for medical purposes outside of the former Soviet Union. The current Special Issue of Viruses contains a collection of papers from opinion leaders in the field who explore hurdles to the introduction of phage therapy in western countries. The articles cover diverse topics ranging from patent to regulatory issues, the targeting of suitable bacterial infections, and the selection and characterization of safe and efficient phage cocktails. Phage resistance is discussed, and gaps in our knowledge of phage–bacterium interactions in the mammalian body are revealed, while other articles explore the use of phages in food production and processing.

Erscheinungsdatum	16.09.2019
Verlagsort	Basel
Sprache	englisch
Maße	170 x 244 mm
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Mikrobiologie / Infektologie / Reisemedizin
Themenwelt	Naturwissenschaften ► Biologie ► Mikrobiologie / Immunologie
Schlagworte	abortive infection • Adaptation • adaptive immunity • Adsorption • Alginate • Animal model • Antibiotic • antibiotic resistance • Antibiotic-resistance • Antibiotic Therapy • Antimicrobial • Antimicrobial Resistance • antimicrobial resistance (AMR) • anti-phage antibodies • atmp • Bacterial disease • bacterial infection • bacterial resistance • Bacteriophage • bacteriophage efficacy • bacteriophages • Bacteriophage therapy • Belgium • Best Practices • Biofilm • Biofilms • Brussels • capsule • capsule depolymerase • cases report • clinical trial • Co-Evolution • Compassionate Use • compounding pharmacy • crop production • Democratic Republic of the Congo • Developing Countries • Disinfection • E. faecalis • Enterococcus • Escherichia coli • Evolution • Experimental Therapy • extended-spectrum beta lactamases (ESBL) • foodborne illness • Food Safety • frequency of resistance • Galleria Mellonella • Gastrointestinal Tract • genomics • Germany • Global Health • High-throughput sequencing • History of Science • horizontal gene transfer • human host • immunology • Immunomodulation • IND • industrial phage application • Infection • infectious disease • Innate Immunity • Kayvirus • Klebsiella pneumoniae • Listeria ivanovii • lysins • magistral formula • magistral preparation • MALDI-MS • Multidrug-resistant bacteria • N/A • nontraditional antibacterial • OrthoMCL • patent landscape • personalised medicines • Personalized medicine • phage • phage biocontrol • phage cocktails • phage-host interactions • phage-human host interaction • phage preparation • phage-resistance • Phages • phage sensitivity • Phage Therapy • phagodisinfection • pharmaceutical legislation • pharmaceutical paradigm shift • pH stability • Production • prophage • Pseudomonas aeruginosa • PTMP • Regulation • Regulatory Framework • resistance • Resistance Management • rhamnopolysaccharide • Salmonella typhi • Science Communication • staphylococcus • Staphylococcus aureus • sustainable agriculture • target selection • therapy • Twortlikevirus • typhoid fever • vB_SauM-fRuSau02 • viral genomes • Viral proteins • Virulence • virus–host interactions • zoonosis
ISBN-10	3-03921-391-1 / 3039213911
ISBN-13	978-3-03921-391-7 / 9783039213917
Zustand	Neuware